Sugi Predict

Sugi Predict / Compounds / SCHEMBL4081435

SCHEMBL4081435

SCHEMBL4081435

N#CCS(=O)(=O)c1ccccn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NFE2L2 Q16236 3/20 0.48
▸ KEAP1 Q14145 1/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ PKM P14618 5/20 0.43
▸ KDM4E B2RXH2 1/20 0.42
▸ RIPK1 Q13546 1/20 0.40
▸ MAOA P21397 1/20 0.40
▸ MAOB P27338 1/20 0.40
▸ LOX P28300 1/20 0.40
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ LMNA P02545 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ POLB P06746 3/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ KMT2A Q03164 2/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ GLO1 Q04760 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8993328 0.76 NFE2L2 (0.49) NFE2L2KEAP1L3MBTL1PKMKDM4E
SCHEMBL4685419 0.76 NFE2L2 (0.49) NFE2L2KEAP1L3MBTL1PKMKDM4E
SCHEMBL30333699 0.76 NFE2L2 (0.49) NFE2L2KEAP1L3MBTL1PKMKDM4E
SCHEMBL4685420 0.75 NFE2L2 (0.47) NFE2L2KEAP1L3MBTL1PKMKDM4E
SCHEMBL26694715 0.75 NFE2L2 (0.47) NFE2L2KEAP1L3MBTL1PKMKDM4E
SCHEMBL1515311 0.75 NFE2L2 (0.47) NFE2L2KEAP1L3MBTL1PKMKDM4E
SCHEMBL11111429 0.75 KDM4E (0.50) NFE2L2KEAP1L3MBTL1PKMKDM4E
SCHEMBL14532278 0.75 NFE2L2 (0.47) NFE2L2KEAP1L3MBTL1PKMKDM4E
SCHEMBL4683019 0.73 NFE2L2 (0.58) NFE2L2KEAP1L3MBTL1PKMKDM4E
SCHEMBL4004512 0.72 NFE2L2 (0.53) NFE2L2KEAP1L3MBTL1PKMKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117209400-B 3-Nitrogen mustard-2-sulfonyl acrylonitrile derivative with anti-tumor activity and preparation method and application thereof 广东海洋大学 2024-04-26 — — CN claimed
US-20060222997-A1 Adhesion improver for photosensitive resin composition and photosensitive resin composition containing same KOBAYASHI SATOSHI 2006-10-05 — — US claimed
CN-117209400-B 3-Nitrogen mustard-2-sulfonyl acrylonitrile derivative with anti-tumor activity and preparation method and application thereof 广东海洋大学 2024-04-26 — — CN disclosed
CN-116836142-B 3-chromone-2-sulfonyl acrylonitrile derivative and preparation method and application thereof 广东海洋大学 2023-12-12 — — CN disclosed
CN-117209400-A 3-nitrogen mustard-2-sulfonyl acrylonitrile derivative with anti-tumor activity and preparation method and application thereof 广东海洋大学 2023-12-12 — — CN disclosed
CN-116836142-A 3-chromone-2-sulfonyl acrylonitrile derivative and preparation method and application thereof 广东海洋大学 2023-10-03 — — CN disclosed
CN-107024834-B Compound and coloring composition 住友化学株式会社 2021-11-23 — — CN disclosed
CN-106019830-B Resist composition and method for producing resist pattern 住友化学株式会社 2021-08-20 — — CN disclosed
CN-107586469-B Pigment composition, coloring composition, and coloring curable composition 住友化学株式会社 2021-04-06 — — CN disclosed
US-10381681-B2 Electrolyte and lithium-ion battery containing the same CONTEMPORARY AMPEREX TECHNOLOGY CO., LIMITED (CN) 2019-08-13 — — US disclosed
US-10059713-B2 3-substituted 2-amino-indole derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-08-28 — — US disclosed
US-6225346-B1 FOR THERAPY AND PROPHYLAXIS OF CELL PROLIFERATIVE DISORDERS OR CELL DIFFERENTIATION DISORDERS ASSOCIATED WITH PARTICULAR TYROSINE KINASES BY INHIBITING ONE OR MORE ABNORMAL TYROSINE KINASE ACTIVITIES SUGEN, INC. 2001-05-01 — — US disclosed
US-5935993-A TYROSINE KINASE INHIBITORS; TREATMENT OF CELL GROWTH, CELL DIFFERENTIATION DISORDERS SUGEN, INC. (US) 1999-08-10 — — US disclosed
US-5891917-A MODULATING TYROSINE SIGNAL TRANSDUCTION TO PREVENT AND TREAT CELL PROLIFERATIVE DISORDERS OR CELL DIFFERENTIATION DISORDERS ASSOCIATED WITH PARTICULAR TYROSINE KINASES BY INHIBITING ONE OR MORE ABNORMAL TYROSINE KINASE ACTIVITIES SUGEN, INC. (US) 1999-04-06 — — US disclosed
US-5886195-A REACTING AN APPROPRIATE CARBOXALDEHYDE WITH AN APPROPRIATE SULFONYLACETONITRILE SUGEN, INC. (US) 1999-03-23 — — US disclosed
US-5789427-A ANTITUMOR, ANTICANCER AGENTS SUGEN, INC. (US) 1998-08-04 — — US disclosed
US-5773476-A KINASE INHIBITORS SUGEN, INC. (IL) 1998-06-30 — — US disclosed
US-5710173-A ANTITUMOR AGENTS OR ANTICARCINOGENIC AGENTS SUGEN, INC. (US) 1998-01-20 — — US disclosed
WO-1996040629-A1 TYRPHOSTIN-LIKE COMPOUNDS FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS OR CELL DIFFERENTIATION DISORDERS SUGEN, INC. (US) 1996-12-19 — — WO disclosed
WO-1996040675-A1 THIENYL COMPOUNDS FOR INHIBITION OF CELL PROLIFERATIVE DISORDERS SUGEN, INC. (US) 1996-12-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10059713-B2 3-substituted 2-amino-indole derivatives NPY5R, XDH, NPY4R NFE2L2 2228/4885KEAP1 2867/4885L3MBTL1 3620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.